These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24602463)

  • 1. Leveraging melanocortin pathways to treat glomerular diseases.
    Gong R
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):134-51. PubMed ID: 24602463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.
    Qiao Y; Berg AL; Wang P; Ge Y; Quan S; Zhou S; Wang H; Liu Z; Gong R
    Sci Rep; 2016 Jun; 6():27589. PubMed ID: 27270328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
    Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
    Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
    Qiao Y; Wang P; Chang M; Chen B; Ge Y; Malhotra DK; Dworkin LD; Gong R
    Clin Sci (Lond); 2020 Apr; 134(7):695-710. PubMed ID: 32167144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanocortin 5 receptor signaling pathway in health and disease.
    Xu Y; Guan X; Zhou R; Gong R
    Cell Mol Life Sci; 2020 Oct; 77(19):3831-3840. PubMed ID: 32248247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The renaissance of corticotropin therapy in proteinuric nephropathies.
    Gong R
    Nat Rev Nephrol; 2011 Dec; 8(2):122-8. PubMed ID: 22143333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanocortin 1 receptor agonists reduce proteinuria.
    Lindskog A; Ebefors K; Johansson ME; Stefánsson B; Granqvist A; Arnadottir M; Berg AL; Nyström J; Haraldsson B
    J Am Soc Nephrol; 2010 Aug; 21(8):1290-8. PubMed ID: 20507942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
    Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W
    Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
    Madan A; Mijovic-Das S; Stankovic A; Teehan G; Milward AS; Khastgir A
    BMC Nephrol; 2016 Mar; 17():37. PubMed ID: 27036111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
    Agrawal V; Prasad N; Jain M; Pandey R
    Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.
    Yang Y; Gubler MC; Beaufils H
    Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities.
    Chang M; Chen B; Shaffner J; Dworkin LD; Gong R
    Front Physiol; 2021; 12():651236. PubMed ID: 33716796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
    Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
    Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezrin--a useful factor in the prognosis of nephrotic syndrome in children: an immunohistochemical approach.
    Ostalska-Nowicka D; Zachwieja J; Nowicki M; Kaczmarek E; Siwinska A; Witt M
    J Clin Pathol; 2006 Sep; 59(9):916-20. PubMed ID: 16522749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing Glomerular Barrier Dysfunction with Patient-Derived Serum in Glomerulus-on-a-Chip Models: Unveiling New Insights into Glomerulonephritis.
    Kim SY; Choi YY; Kwon EJ; Seo S; Kim WY; Park SH; Park S; Chin HJ; Na KY; Kim S
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of B7-1 in proteinuria of glomerular origin.
    Novelli R; Benigni A; Remuzzi G
    Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multifunctional human ocular melanocortin system.
    Wu CS; Cioanca AV; Gelmi MC; Wen L; Di Girolamo N; Zhu L; Natoli R; Conway RM; Petsoglou C; Jager MJ; McCluskey PJ; Madigan MC
    Prog Retin Eye Res; 2023 Jul; 95():101187. PubMed ID: 37217094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.
    Bomback AS; Tumlin JA; Baranski J; Bourdeau JE; Besarab A; Appel AS; Radhakrishnan J; Appel GB
    Drug Des Devel Ther; 2011 Mar; 5():147-53. PubMed ID: 21448451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary glomerular disease: to treat or not to treat.
    Donadio JV
    Contrib Nephrol; 1982; 33():86-103. PubMed ID: 7116871
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.
    Manabe S; Nitta K; Nagata M
    Contrib Nephrol; 2018; 195():131-142. PubMed ID: 29734158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.